In addiction, Jarius and colleagues [41] have confirmed that a cell-based or a novel fluorescence-based immunoprecipitation assay that employs recombinant human AQP4 coupled to GFP has higher sensitivity and specificity for NMO than does the NMO-IgG assay. Here, AQP4 is linked to neuromyelitis optica.